SRSD216 / Sirius Therap - LARVOL DELTA

SRSD216 a Novel siRNA Therapeutic Provides Sustained Durable Reductions in Lipoprotein(a) up to 1 Year After a Single Dose- A Phase 1 Dose-Escalation Study (AHA 2026) - No abstract available

P1 data

SRSD216 a Once Yearly Novel Small Interfering RNA Therapeutic to Lipoprotein(a) Provides Time Averaged Annualized Reduction of 85% After a Single Dose A Phase 1 Study (AHA 2026) - No abstract available

Late-breaking abstract • P1 data

A Study of SRSD216 in Patients With Elevated Lipoprotein (a) (clinicaltrials.gov) - P1/2 | N=84 | Recruiting | Sponsor: Sirius Therapeutics Co., Ltd. | N=48 ➔ 84

Enrollment change • Dyslipidemia • Metabolic Disorders

A Study of SRSD216 in Patients With Elevated Lipoprotein (a) (clinicaltrials.gov) - P1/2 | N=48 | Recruiting | Sponsor: Sirius Therapeutics Co., Ltd.

New P1/2 trial • Dyslipidemia • Metabolic Disorders